Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT05648396
Active, not recruiting Observational

Japan FFRangio Clinical Outcomes Study

NCT05648396 · tracked via the Priya Life Science Israel tracker
Sponsor
Rabin Medical Center
Phase
Observational
Started
2022-11-07
Last updated
2022-12-13

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

FFRangio

FFRangio: Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.

Study summary

This study aims to collect data on clinical outcomes of real world patients undergoing FFRangio guided treatment for coronary artery disease in Japan and Israel through a retrospective multicentre registry.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion criteria: • Patients undergoing coronary angiogram for a clinical indication, for whom FFRangio is used to assess the physiologic significance of at least 1 coronary lesion and guide the treatment decisions. Exclusion criteria: * Culprit lesion of a STEMI (patients undergoing PCI for non-culprit lesions can be included if the culprit lesion has been successfully treated prior to the non-culprit PCI * Presence of significant (moderate+) valvular heart disease * Chronic total occlusion in one of the coronary arteries * Isolated significant left main disease * Prior coronary artery bypass graft surgery * Clinical presentation of cardiogenic shock or severe LV dysfunction * Coronary anomalies

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Rabin Medical Centre Petah Tikva Israel

More Rabin Medical Center trials in Israel

Deep Brain Stimulation Surgery for the Treatment of Refractory Obsessive-Compulsive Disorder Recruiting
Carb Counting vs. Simplified Qualitative Meal-Size Estimation Recruiting
Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction Recruiting
Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial. Recruiting
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors Recruiting

Other trials for the same condition

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial Active, not recruiting
Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting Enrolling by invitation
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions Recruiting
TECTONIC CAD IVL IDE Study Active, not recruiting
SELUTION 4 De Novo Small Vessel IDE Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05648396 on ClinicalTrials.gov ↗ ← All trials in Israel